Reata Pharmaceuticals Inc - ESG Rating & Company Profile powered by AI
The report of Reata Pharmaceuticals Inc employs information from across the web and also from public filings by Reata Pharmaceuticals Inc. Jump to the end of the webpage for potential risks for Reata Pharmaceuticals Inc based on industry, location and marketcap. The article includes a questions and answers table on Reata Pharmaceuticals Inc.
Reata Pharmaceuticals Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 1.2; made up of an environmental score of 0.0, social score of 2.3 and governance score of 1.3.
1.2
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1755 | TRACON Pharmaceuticals Inc | 1.3 | Low |
1755 | Trimurthi Ltd | 1.3 | Low |
1779 | Reata Pharmaceuticals Inc | 1.2 | Low |
1779 | Cell Biotech Co Ltd | 1.2 | Low |
1779 | Aurisco Pharmaceutical Co Ltd | 1.2 | Low |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Reata Pharmaceuticals Inc have an accelerator or VC vehicle to help deliver innovation?
Does Reata Pharmaceuticals Inc disclose current and historical energy intensity?
Does Reata Pharmaceuticals Inc report the average age of the workforce?
Does Reata Pharmaceuticals Inc reference operational or capital allocation in relation to climate change?
Does Reata Pharmaceuticals Inc disclose its ethnicity pay gap?
Does Reata Pharmaceuticals Inc disclose cybersecurity risks?
Does Reata Pharmaceuticals Inc offer flexible work?
Does Reata Pharmaceuticals Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Reata Pharmaceuticals Inc disclose the number of employees in R&D functions?
Does Reata Pharmaceuticals Inc conduct supply chain audits?
Does Reata Pharmaceuticals Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Reata Pharmaceuticals Inc conduct 360 degree staff reviews?
Does Reata Pharmaceuticals Inc disclose the individual responsible for D&I?
Does Reata Pharmaceuticals Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Reata Pharmaceuticals Inc disclose current and / or historical scope 2 emissions?
Does Reata Pharmaceuticals Inc disclose water use targets?
Does Reata Pharmaceuticals Inc have careers partnerships with academic institutions?
Did Reata Pharmaceuticals Inc have a product recall in the last two years?
Does Reata Pharmaceuticals Inc disclose incidents of discrimination?
Does Reata Pharmaceuticals Inc allow for Work Councils/Collective Agreements to be formed?
Has Reata Pharmaceuticals Inc issued a profit warning in the past 24 months?
Does Reata Pharmaceuticals Inc disclose parental leave metrics?
Does Reata Pharmaceuticals Inc disclose climate scenario or pathway analysis?
Does Reata Pharmaceuticals Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Reata Pharmaceuticals Inc disclose the pay ratio of women to men?
Does Reata Pharmaceuticals Inc support suppliers with sustainability related research and development?
Does Reata Pharmaceuticals Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Reata Pharmaceuticals Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Reata Pharmaceuticals Inc involved in embryonic stem cell research?
Does Reata Pharmaceuticals Inc disclose GHG and Air Emissions intensity?
Does Reata Pharmaceuticals Inc disclose its waste policy?
Does Reata Pharmaceuticals Inc report according to TCFD requirements?
Does Reata Pharmaceuticals Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Reata Pharmaceuticals Inc disclose energy use targets?
Does Reata Pharmaceuticals Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Reata Pharmaceuticals Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Reata Pharmaceuticals Inc
These potential risks are based on the size, segment and geographies of the company.
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.